Geneva, Aug. 5 -- International Clinical Trials Registry received information related to the study (ACTRN12625000764437) titled 'Can Dexamphetamine Help with Weight Loss? A Study in Primary Care' on July 18.
Study Type: Interventional
Study Design:
Purpose: Treatment
Allocation: Randomised controlled trial
Masking: Blinded (masking used)
Type of endpoint: Efficacy
Primary Sponsor: Nepean Hospital
Condition:
Obesity
Obesity
Diet and Nutrition - Obesity
Intervention:
Dexamphetamine will be administered orally at a starting dose of 5 mg twice daily, with weekly titration over a six-week period to a maximum dose of 60 mg twice daily, based on adverse events and individual tolerance. The medication will be prescribed in tablet form, an...